Received: 11 January 2022
Accepted: 3 October 2022
We thank the EPIC RCHCI staff and management and the ETHZ animal welfare officers for their great support with animal experiments. We also thank the Scientific Center for Optical and Electron Microscopy (ScopeM) and the Flow Cytometry Core Facility at ETH-Zürich for access to facilities. We thank D. C. Bono for useful input for the magnetometer design, L. Amoudruz for helpful discussions on computational modeling of MTB, L. Stöcklin for assistance with the inductive detection experiments, and D. Dubey for providing helpful feedback on the manuscript.
Funding: This work is supported by the Branco Weiss Fellowship—Society in Science (title: “Cancer-fighting magnetic biobots: Harnessing the power of synthetic biology and magnetism”) and funding from Takeda Pharmaceuticals (title: “Feasibility study: Penetration ability of magnetotactic bacteria”). T.G. was supported by a Swiss Government Excellence Scholarship.
Author contributions: Conceptualization: S.S., T.G., N.M., M.G.C., and V.L. Methodology: S.S., T.G., N.M., and M.G.C. Investigation: T.G., N.M., M.G.C., T.T.N., and S.S. Visualization: T.G. Supervision: S.S. Writing—original draft: T.G. Writing—review and editing: S.S., T.G., M.G.C., N.M., T.T.N., and V.L.
Competing interests: S.S. is co-founder, technical advisor, and member of the board of MagnebotiX AG and member of the board of Quercis Pharma. AG. V.L. is an employee of Takeda Pharmaceuticals. The authors declare that they have no other competing interests.
Data and materials availability: All data needed to support the conclusions of this manuscript are included in the main text or Supplementary Materials. Additional data related to this paper may be requested from the authors.